Autoimmune Myopathies: Updates on Evaluation and Treatment

Area of Science:

• Neurology
• Immunology
• Rheumatology

Background:

• Autoimmune myopathies encompass dermatomyositis (DM), polymyositis (PM), antisynthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM).
• These distinct conditions share an immune-mediated etiology and can present independently or alongside systemic malignancies or connective tissue disorders.
• Existing classification systems inadequately capture shared clinical features and prognostic indicators.

Purpose of the Study:

• To review the current understanding of autoimmune myopathies.
• To highlight the role of myositis-specific autoantibodies in refining classification and predicting outcomes.
• To discuss current and emerging therapeutic approaches.

Main Methods:

• Review of existing literature and observational data.
• Analysis of the utility of myositis-specific autoantibodies in clinical practice.
• Evaluation of current treatment guidelines and expert opinions.

Main Results:

• Myositis-specific autoantibodies correlate with specific clinical and histopathological phenotypes.
• These autoantibodies provide valuable prognostic information regarding malignancy risk and treatment response.
• Corticosteroids are first-line for DM, PM, ASS, and IMNM; IVIG is an alternative for statin-induced IMNM.

Conclusions:

• A classification system based on myositis-specific autoantibodies offers improved patient stratification and prognostic insights.
• Optimal selection and timing of second-line therapies require further prospective investigation.
• Personalized treatment approaches informed by autoantibody profiles are crucial for managing autoimmune myopathies.